KalshiKullanılabilirliği kontrol etKYC gerekli%2 ücretGüncel ima edilen olasılıkBefore Jan 1, 2027 17%-11.0%5 seçenek arasında lider
Piyasa kalitesi
28 / 100
Düşük kalite24s Hacim
₺272,1
Likidite
₺3,9 B
Düşük likiditeAlis / Satis
15.0% / 22.0%
Spread
46.7%
Geniş spreadPiyasa verileri
9 dakika önce guncellendi
14 May 26 2:001 Oca 27 4:59
Trendler
Seçilen sonuç
Before Jan 1, 202717%
Polymarket üzerinde de mevcut
FDA approves Retatrutide this year?
1.0%6ay
-0.0%12%
+0.0%89%
52 • Orta kaliteGeniş spreadOrta likidite
Toplam Hacim₺26,3 Mn
24s Hacim₺12,7 B
POLYMARKETKurallar
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals:
Olasılıklar farklı piyasa yapıları, ücretler ve katılımcı havuzları nedeniyle değişiklik gösterebilir.
İlgili Piyasalar
Hantavirus pandemic in 2026?
₺7,9 MnEvet: 5%POLYMARKET
POLYMARKET
New pandemic in 2026?
₺886,8 BEvet: 10%POLYMARKET
POLYMARKET
How many movies will gross >$1 billion in 2026?
₺67 B0-3: 5.7%MANIFOLD MARKETS
MANIFOLD MARKETSWhich disease will be eradicated next in humans?
₺24,7 BPolio: 26.7%MANIFOLD MARKETS
MANIFOLD MARKETS
When, where or how will Trump die?
₺7,3 B2025: 0%MANIFOLD MARKETS
MANIFOLD MARKETSBu konularda aktif
İlgili Haberler
Chainalysis reveals $100 million peptide market built on cryptoCrypto News
Gray peptide vendors embrace stablecoins as safety fears deepenCrypto News
OpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News
Brian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto NewsKurallar
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: